Increasing PET Use in Small Cell Lung Cancer: Survival Improvement and Stage Migration in the VA Central Cancer Registry

Julian C. Hong, Matthew J. Boyer, Daphna Y. Spiegel, Christina D. Williams, Betty Tong, Scott Shofer, Michael J. Moravan, Michael J. Kelley, Joseph K. SalamaJournal of the National Comprehensive Cancer Network 2019 · DOI

TL;DR

This study reveals that the increased adoption of PET scans for staging small cell lung cancer (SCLC) between 2001 and 2010 in the VA system led to improved survival rates for both limited-stage (LS-SCLC) and extensive-stage (ES-SCLC) patients. This improvement is likely due to more accurate staging, which allows for more appropriate treatment and a phenomenon called "stage migration."

What Problem Does This Paper Address?

Accurate staging is crucial for determining the best treatment for small cell lung cancer (SCLC). While the benefits of PET (Positron Emission Tomography) scans in improving staging and outcomes have been well-documented for non-small cell lung cancer (NSCLC), their impact on SCLC has been less clear. This paper aims to fill that knowledge gap by investigating how the increasing use of PET scans for SCLC staging in the Veterans Affairs (VA) healthcare system between 2001 and 2010 affected patient survival and led to changes in how the disease was staged.

Methods

The researchers analyzed data from the Veterans Affairs Central Cancer Registry (VACCR) for patients diagnosed with SCLC between 2001 and 2010. They tracked the use of PET staging over time and assessed overall survival (OS) and lung cancer-specific survival (LCSS). The study specifically examined the impact of PET staging on OS and LCSS for both limited-stage (LS-SCLC) and extensive-stage (ES-SCLC) patients. To account for potential biases, they employed multivariate adjustment and propensity-matching techniques, particularly for the LS-SCLC cohort treated with concurrent chemoradiotherapy.

Datasets

The primary dataset used was the Veterans Affairs Central Cancer Registry (VACCR). This registry is a mandatory, quality-assured nationwide database of all veterans diagnosed with cancer within the Veterans Health Administration (VHA). It was linked with other VA administrative databases, including the VA electronic medical record (EMR) and the VA Corporate Data Warehouse (CDW), as well as the National Death Index (NDI) for survival data.

Key Insights and Ideas

  • PET as a Driver of Stage Migration: The study strongly suggests that increased PET use led to "stage migration." This means that more patients were accurately identified as having more advanced disease (ES-SCLC) than might have been caught with older staging methods, which in turn allowed for more appropriate treatment.
  • Survival Benefits Across Stages: The positive impact of PET staging wasn't limited to one stage of SCLC. Both LS-SCLC and ES-SCLC patients who underwent PET staging showed improved survival outcomes.
  • Importance of Accurate Staging for Therapy: The findings underscore that precise staging is not just an administrative detail but directly influences treatment decisions and, consequently, patient outcomes.
  • Routine PET Use Supported: The results provide strong evidence to support the routine use of PET scans for staging SCLC.

Key Results

  • Increased PET Use: PET use in SCLC patients increased dramatically from 1.1% in 2001 to 39.2% in 2010.
  • Improved Survival: Median overall survival (OS) improved for all SCLC patients (from 6.2 to 7.9 months), LS-SCLC patients (from 10.9 to 13.2 months), and ES-SCLC patients (from 5.0 to 7.0 months) during the study period.
  • Stage Migration Observed: Among patients who received PET staging, the proportion diagnosed with ES-SCLC increased from 63.9% to 65.7%.
  • Significant Survival Gains with PET in LS-SCLC: For LS-SCLC patients treated with chemoradiotherapy, those staged with PET had significantly longer OS (median 19.8 vs. 14.3 months) and LCSS (median 22.9 vs. 16.7 months) compared to those without PET staging, even after accounting for other factors.
  • Survival Gains in ES-SCLC: Similarly, patients with ES-SCLC who underwent PET staging also showed improved OS and LCSS.

Limitations and Future Work

The authors acknowledge several limitations:

  • Selection Bias: Patients who receive PET scans might have better access to advanced care or other unmeasured factors that influence outcomes. While propensity matching was used, it cannot fully eliminate all potential biases.
  • Data Limitations: Local recurrence was not available as an endpoint, and the use of prophylactic cranial irradiation (PCI) could not be precisely identified.
  • Confounding Factors in ES-SCLC: The analysis of ES-SCLC was confounded by evolving treatment paradigms, including the increasing use of PCI and thoracic RT for responders.

Future work could focus on addressing these limitations, potentially through prospective studies or by analyzing more granular data on treatment details and patient access to care. The findings strongly support the continued and routine use of PET staging in SCLC management.

Summary updated

Abstract

<b>Background:</b> Accurate staging for small cell lung cancer (SCLC) is critical for determining appropriate therapy. The clinical impact of increasing PET adoption and stage migration is well described in non-small cell lung cancer but not in SCLC. The objective of this study was to evaluate temporal trends in PET staging and survival in the Veterans Affairs Central Cancer Registry and the impact of PET on outcomes. <b>Patients and Methods:</b> Patients diagnosed with SCLC from 2001 to 2010 were identified. PET staging, overall survival (OS), and lung cancer-specific survival (LCSS) were assessed over time. The impact of PET staging on OS and LCSS was assessed for limited-stage (LS) and extensive-stage (ES) SCLC. <b>Results:</b> From 2001 to 2010, PET use in a total of 10,135 patients with SCLC increased from 1.1% to 39.2%. Median OS improved for all patients (from 6.2 to 7.9 months), those with LS-SCLC (from 10.9 to 13.2 months), and those with ES-SCLC (from 5.0 to 7.0 months). Among staged patients, the proportion of ES-SCLC increased from 63.9% to 65.7%. Among 1,536 patients with LS-SCLC treated with concurrent chemoradiotherapy, 397 were staged by PET. In these patients, PET was associated with longer OS (median, 19.8 vs 14.3 months; hazard ratio [HR], 0.78; 95% CI, 0.68-0.90; <i>P</i><.0001) and LCSS (median, 22.9 vs 16.7 months; HR, 0.74; 95% CI, 0.63-0.87; <i>P</i><.0001) with multivariate adjustment and propensity-matching. In the 6,143 patients with ES-SCLC, PET was also associated with improved OS and LCSS. <b>Conclusions:</b> From 2001 to 2010, PET staging increased in this large cohort, with a corresponding relative increase in ES-SCLC. PET was associated with greater OS and LCSS for LS-SCLC and ES-SCLC, likely reflecting stage migration and stage-appropriate therapy. These findings emphasize the importance of PET in SCLC and support its routine use.
BibTeX
@article{hong2019increasing,
  author = {Julian C. Hong and Matthew J. Boyer and Daphna Y. Spiegel and Christina D. Williams and Betty Tong and Scott Shofer and Michael J. Moravan and Michael J. Kelley and Joseph K. Salama},
  title = {{Increasing PET Use in Small Cell Lung Cancer: Survival Improvement and Stage Migration in the VA Central Cancer Registry}},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2019},
  doi = {10.6004/jnccn.2018.7090},
}
Figure